• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by F-star Therapeutics, Inc.

    5/18/21 4:32:04 PM ET
    $FSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FSTX alert in real time by email
    SC 13G 1 f051821a.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
    (Name of Issuer)
    F-star Therapeutics, Inc.
    (Title of Class of Securities)
    Common Stock, $0.0001 Par Value Per Share

    (CUSIP Number)

    30315R107
    (Date of Event Which Requires Filing of this Statement)
    May 11, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 30315R107
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,100,000 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,100,000 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,100,000 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 30315R107
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,100,000 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power   1,100,000 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,100,000 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.7% (see Item 4)
     
    (12) Type of reporting person (see instructions)   CO
     


    CUSIP No. 30315R107
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,100,000 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,100,000 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,100,000 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    F-star Therapeutics, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    Eddeva B920 Babraham Research Campus, Cambridge, United Kingdom CB22 3AT
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, $0.0001 par value per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management and Point72 Capital Advisors
    Inc.


    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have
    entered into a Joint Filing Agreement, a copy of which is filed with this
    Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this
    Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the
    Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, $0.0001 Par Value Per Share
    2(e) CUSIP Number:
    30315R107

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on May 17, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 1,100,000
    (b) Percent of class: 5.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,100,000 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,100,000

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 1,100,000
    (b) Percent of class: 5.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,100,000 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,100,000

    3. Steven A. Cohen
    (a) Amount beneficially owned: 1,100,000
    (b) Percent of class: 5.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,100,000 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,100,000
    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own
    directly no Shares. Pursuant to an investment management agreement, Point72
    Asset Management maintains investment and voting power with respect to the
    securities held by certain investment funds it manages. Point72 Capital
    Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen
    controls each of Point72 Asset Management and Point72 Capital Advisors Inc.
    By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934,
    as amended, each of Point72 Asset Management, Point72 Capital Advisors
    Inc. and Mr. Cohen may be deemed to beneficially own 1,100,000 Shares
    (constituting approximately 5.7% of the Shares outstanding). Each of Point72
    Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen disclaims
    beneficial ownership of any of the securities covered by this statement.
    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group
    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: May 18, 2021

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $FSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FSTX

    DatePrice TargetRatingAnalyst
    7/15/2022$35.00 → $7.00Buy → Neutral
    H.C. Wainwright
    11/18/2021$15.00Buy
    Ladenburg Thalmann
    8/17/2021$39.00 → $35.00Outperform
    SVB Leerink
    7/8/2021$39.00Outperform
    SVB Leerink
    More analyst ratings

    $FSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

      invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

      3/8/23 7:30:00 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • F-star Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded F-star Therapeutics from Buy to Neutral and set a new price target of $7.00 from $35.00 previously

      7/15/22 7:26:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on F-star Therapeutics with a new price target

      Ladenburg Thalmann resumed coverage of F-star Therapeutics with a rating of Buy and set a new price target of $15.00

      11/18/21 9:22:57 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on F-star Therapeutics with a new price target

      SVB Leerink reiterated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $35.00 from $39.00 previously

      8/17/21 6:30:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Kayitalire Louis returned $178,135 worth of shares to the company (25,019 units at $7.12), closing all direct ownership in the company to satisfy tax liability

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:21:33 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Forster Eliot returned $526,588 worth of shares to the company (73,959 units at $7.12), closing all direct ownership in the company (for withholding tax)

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:20:14 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Klein Pamela M.

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:18:56 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by F-star Therapeutics Inc.

      SC 13G - F-star Therapeutics, Inc. (0001566373) (Subject)

      3/17/23 4:23:46 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

      SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)

      2/14/23 4:06:44 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

      SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)

      2/14/23 4:02:47 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Financials

    Live finance-specific insights

    See more
    • invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

      invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

      3/8/23 7:30:00 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

      Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX Pharma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE)

      8/11/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual MeetingCompany To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update. "This year is one of the most important yea

      5/10/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • F-star Therapeutics Appoints James Sandy as Chief Development Officer

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today. Mr. Sandy will lead the clinical development and advancement of F-star's pipeline. "We are delighted to welcome James to F-star," said Eliot Forster, CEO of F-star Therapeutics, Inc. "James brings an unparalleled depth of experience in drug development in oncology and a strong track record of enhancing and accelerating clin

      3/1/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by F-star Therapeutics Inc.

      15-12G - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/20/23 9:06:42 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by F-star Therapeutics Inc.

      EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/14/23 12:15:07 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by F-star Therapeutics Inc.

      EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/14/23 12:15:12 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care